About: Chronic obstructive pulmonary disease in China: a nationwide prevalence study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chronic obstructive pulmonary disease in China: a nationwide prevalence study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Chronic obstructive pulmonary disease in China: a nationwide prevalence study
Creator	Wang, Ning Gao, Pei Bao, Heling Cong, Shu Fan, Jing Fang, Liwen Feng, Yajing Hu, Yonghua Juan, Juan Lu, Ke Tang, Xun Wang, Baohua Wang, Linhong
topic	covid:aff980a3b552e184251a190f2f50f4507a92087b#this
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Because of the rapid change in economic development and lifestyle in China, and the ageing population, concerns have grown that chronic obstructive pulmonary disease (COPD) could become epidemic. An up-to-date nationwide estimation of COPD prevalence in China is needed. METHODS: We did a cross-sectional survey of a nationally representative sample of individuals from mainland China aged 40 years or older. The primary outcome was COPD, defined according to the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) lung function criteria. FINDINGS: Between Dec 29, 2014, and Dec 31, 2015, 66 752 adults were recruited to the study population. The estimated standardised prevalence of COPD was 13·6% (95% CI 12·0–15·2). The prevalence of COPD differed significantly between men and women (19·0%, 95% CI 16·9–21·2 vs 8·1%, 6·8–9·3; p<0·0001), mainly because of a significant difference in smoking status between men and women (current smokers 58·2% vs 4·0%). The prevalence of COPD differed by geographic region, with the highest prevalence in southwest China (20·2%, 95% CI 14·7–25·8) and the lowest in central China (10·2%, 8·2–12·2). Among adults with COPD, 56·4% (95% CI 53·7–59·2) had mild disease (GOLD stage I), 36·3% (34·3–38·3) had moderate disease (GOLD stage II), 6·5% (5·5–7·4) had severe disease (GOLD stage III), and 0·9% (0·6–1·1) had very severe disease (GOLD stage IV). INTERPRETATION: In a large, nationally representative sample of adults aged 40 years or older, the estimated overall prevalence of COPD in China in 2014–15 was 13·6%, indicating that this disease has become a major public-health problem. Strategies aimed at prevention and treatment of COPD are needed urgently. FUNDING: Chinese Central Government, the Ministry of Science and Technology of The People's Republic of China, and the National Natural Science Foundation of China.
has issue date	2018-04-09(xsd:dateTime)
bibo:doi	10.1016/s2213-2600(18)30103-6
bibo:pmid	29650407
has license	no-cc
sha1sum (hex)	aff980a3b552e184251a190f2f50f4507a92087b
schema:url	https://doi.org/10.1016/s2213-2600%2818%2930103-6
resource representing a document's title	Chronic obstructive pulmonary disease in China: a nationwide prevalence study
has PubMed Central identifier	PMC7185405
has PubMed identifier	29650407
schema:publication	Lancet Respir Med
resource representing a document's body	covid:aff980a3b552e184251a190f2f50f4507a92087b#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/aff980a3b552e184251a190f2f50f4507a92087b
is schema:about of	named entity 'chronic obstructive pulmonary disease (COPD)' named entity 'China' named entity 'CHRONIC OBSTRUCTIVE PULMONARY DISEASE' named entity 'EPIDEMIC' named entity 'BACKGROUND' named entity 'RAPID' named entity 'ESTIMATION' named entity 'CHINA' named entity 'AGEING' named entity 'DATE' named entity 'CHINA' named entity 'PREVALENCE STUDY' named entity 'ARTICLES' named entity 'CONCERNS' named entity 'ECONOMIC DEVELOPMENT' named entity 'CHRONIC OBSTRUCTIVE PULMONARY DISEASE' named entity 'LIFESTYLE' named entity 'PREVALENCE' named entity 'NEEDED' named entity 'POPULATION' named entity 'COPD' named entity 'CHANGE IN' named entity 'HAVE' covid:arg/aff980a3b552e184251a190f2f50f4507a92087b named entity 'economic development' named entity 'China' named entity 'economic development' named entity 'COPD' named entity 'Chronic obstructive pulmonary disease' named entity 'China' named entity 'FEV' named entity 'COPD' named entity 'China' named entity 'data collection' named entity 'FVC' named entity 'representative sample' named entity 'cigarette smoking' named entity 'FEV' named entity 'disease burden' named entity 'Wanfang' named entity 'spirometry' named entity 'carbon monoxide' named entity 'CNKI' named entity 'Montevideo' named entity 'COPD' named entity 'urban cohorts' named entity 'bronchodilator' named entity 'China National Knowledge Infrastructure' named entity 'stage II' named entity 'smokers' named entity 'COPD' named entity 'COPD' named entity '95% CI' named entity 'occupational exposure' named entity 'Medical Research Council' named entity 'mercury' named entity 'bronchodilator' named entity '95% CI' named entity 'recall bias' named entity 'COPD' named entity 'spirometry' named entity 'spirometry' named entity 'stage II' named entity 'COPD' named entity 'coal' named entity '95% CI' named entity 'COPD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software